Evidence Grade A — Regulatory approved. 38 published studies. 7 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Palopegteriparatide (sold as Yorvipath) is the first and only hormone replacement therapy for hypoparathyroidism — a condition where the parathyroid glands do not produce enough hormone to regulate calcium, leaving patients dependent on high doses of calcium supplements and vitamin D just to maintain safe blood calcium levels. Given as a single daily injection, it slowly releases parathyroid hormone throughout the day.
Palopegteriparatide is also known by these brand and alternate names:
38 published studies: 19 human, 0 animal, 0 in-vitro, 13 reviews
Palopegteriparatide is marketed as Yorvipath (Ascendis Pharma, approved August 2024). It is the first FDA-approved PTH replacement therapy for hypoparathyroidism, a condition that previously had no approved hormone replacement and was managed only with high doses of calcium supplements and active vitamin D — an approach that does not fully normalise calcium metabolism.
In the PaTHway trial, 79% of patients achieved independence from calcium and active vitamin D supplements while maintaining normal blood calcium levels, compared to 5% on placebo. This represents a fundamental shift in managing hypoparathyroidism — from supplementation to actual hormone replacement. Patients also showed improvements in kidney function markers and bone metabolism parameters.
Palopegteriparatide is a prodrug: the active parathyroid hormone fragment (PTH 1-34) is attached to a large carrier molecule (PEG) via a chemical linker that slowly breaks down at body temperature and pH. This gradually releases the active hormone over 24 hours, mimicking the continuous parathyroid hormone production that patients with hypoparathyroidism lack. The released PTH then regulates calcium and phosphorus metabolism through the same pathways as the body's natural hormone.
In the PaTHway trial, 79% of patients on palopegteriparatide achieved independence from calcium and active vitamin D supplements while maintaining normal blood calcium levels, compared to just 5% on placebo. This represents a fundamental shift from managing symptoms to actually replacing the missing hormone — comparable to how insulin replacement transformed diabetes care. Before Yorvipath, there was no dedicated treatment for hypoparathyroidism. The conventional approach (high-dose calcium and active vitamin D) does not restore normal calcium metabolism and carries risks of kidney damage from excessive calcium excretion. The hypoparathyroidism population is relatively small (approximately 70,000 diagnosed patients in the US). Post-marketing surveillance is monitoring long-term effects on bone health and kidney function.
PeptideTrace tracks 7 registered clinical trials for Palopegteriparatide sourced from ClinicalTrials.gov.
Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
Translation and Validation of the Hypoparathyroidism Patient Experience Scales (HPES) Questionnaire in Greek
EMA Marketing Authorisation
FDA ORIG 1
FDA SUPPL 5
Palopegteriparatide is a prodrug consisting of PTH(1-34) covalently attached to a polyethylene glycol (PEG) carrier via a proprietary TransCon (transient conjugation) linker technology developed by Ascendis Pharma. The PEG carrier inactivates the PTH(1-34) molecule; controlled hydrolysis of the linker releases active PTH(1-34) continuously over 24 hours.
Upon subcutaneous injection, the TransCon linker slowly hydrolyzes at physiological pH and temperature, releasing unmodified PTH(1-34) in a sustained, controlled manner. This produces continuous PTH1R activation, which in the hypoparathyroid context restores physiological calcium homeostasis, phosphate balance, and bone turnover. This continuous delivery differs fundamentally from teriparatide's once-daily bolus, which is designed for the intermittent/anabolic osteoporosis paradigm.
Palopegteriparatide is marketed as Yorvipath (Ascendis Pharma, FDA approved August 12, 2024). It is the first and only FDA-approved PTH replacement therapy for hypoparathyroidism, a condition previously managed only with calcium supplements and active vitamin D analogues. The PaTHway trial (N=82; 26 weeks) demonstrated that 78.7% of patients achieved the primary composite endpoint (serum calcium normalization plus independence from conventional therapy) versus 4.8% with placebo (P<0.0001). Overall, 95% achieved independence from active vitamin D and calcium supplements.
Linaclotide is marketed as Linzess (approved August 2012). It is taken as a daily oral capsule on an empty stomach, at least 30 minutes before the first meal. The recommended dose is 290 mcg for IBS-C and 72 or 145 mcg for chronic constipation. In clinical trials, approximately 34% of IBS-C patients met the composite improvement endpoint compared to 17% on placebo. Diarrhoea is the most common side effect (approximately 20%) and the leading reason for discontinuation. Linaclotide has a boxed warning against use in children under 6 years due to deaths in young mice, though no such events have been reported in humans. It competes with plecanatide (which targets the same pathway) and other IBS-C treatments.
Elamipretide (Forzinity) was approved by the FDA for Barth syndrome based on the TAZPOWER trial. The randomised crossover phase (12 patients) did not meet its primary endpoints, but the open-label extension (168 weeks) demonstrated durable improvements in walking distance and muscle strength that formed the basis for approval. Barth syndrome affects approximately 1 in 300,000–400,000 births. A larger Phase III trial in primary mitochondrial myopathy (218 patients, MMPOWER-3) did not meet its primary endpoint, and the drug was not approved for that broader indication. Elamipretide remains approved exclusively for Barth syndrome. See also SS-31 (#158) for the research compound context.
Glucagon has been available as an emergency injection since the 1960s and remains the standard rescue treatment for severe hypoglycaemia. Recent innovation has focused on making it easier to administer in emergencies. Baqsimi, approved in 2019, was the first needle-free option as a nasal powder. Gvoke, also approved in 2019, eliminated the need to mix and reconstitute the medication before injection — a significant advance since severe hypoglycaemia often impairs the ability to follow complex preparation steps. Dasiglucagon (Zegalogue), a next-generation stable liquid glucagon approved in 2021, further improved on the convenience of rescue administration. Beyond emergency rescue, glucagon's receptor is now a major research target — dual and triple agonists combining glucagon receptor activity with GLP-1 (such as survodutide and retatrutide) are in advanced clinical trials for obesity and metabolic disease.
Evidence Reviews
Deep Dives
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
